Page 11234..1020..»

NHS Surgeon First in Europe to Implant TELA Bio’s OviTex® LPR Reinforced Tissue Matrix

By Dr. Matthew Watson

Mr. Paul Wilson, Consultant General Surgeon, successfully completes complex hernia repair with minimally invasive approach Mr. Paul Wilson, Consultant General Surgeon, successfully completes complex hernia repair with minimally invasive approach

See the original post:
NHS Surgeon First in Europe to Implant TELA Bio's OviTex® LPR Reinforced Tissue Matrix

To Read More: NHS Surgeon First in Europe to Implant TELA Bio’s OviTex® LPR Reinforced Tissue Matrix
categoriaGlobal News Feed commentoComments Off on NHS Surgeon First in Europe to Implant TELA Bio’s OviTex® LPR Reinforced Tissue Matrix | dataJuly 22nd, 2021
Read All

Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference

By Dr. Matthew Watson

- On Monday, July 26th, New Clinical Data for SavaDx to be Shared ina Poster Presentation -

Read more:
Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference

To Read More: Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference
categoriaGlobal News Feed commentoComments Off on Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference | dataJuly 22nd, 2021
Read All

Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021

By Dr. Matthew Watson

LA JOLLA, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that Ladenburg Thalmann & Co. Inc. will host an R&D showcase focused on the Phase 1b/2a Cancer Appetite Recovery Study (“CAReS”), evaluating the Company’s lead drug candidate, ART27.13. The webinar will be hosted by Michael Higgins, Managing Director and Senior Biopharmaceutical Equity Research Analyst on July 28th, 2021 at 1pm EDT/10am PDT. This event will include the lead investigator on the CAReS study, Barry Laird, PhD, a Senior Clinical Consultant of Palliative Medicine at St Columba's Hospice Care in Edinburg, UK. Among a number of key topics, Dr. Laird will be discussing the etiology of anorexia and the accompanying challenges of effectively treating anorexia.

Read the original:
Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021

To Read More: Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021
categoriaGlobal News Feed commentoComments Off on Ladenburg Thalmann to Host R&D Showcase Featuring Artelo Biosciences’ CAReS Study on July 28, 2021 | dataJuly 22nd, 2021
Read All

Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021

By Dr. Matthew Watson

CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2021 financial results and business highlights.

See original here:
Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021

To Read More: Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021
categoriaGlobal News Feed commentoComments Off on Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021 | dataJuly 22nd, 2021
Read All

Tauriga Sciences Inc. Commences Sales of its Tauri-Gum Product Line in the United Kingdom

By Dr. Matthew Watson

NEW YORK, NY, July 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced that it has commenced sales of its Tauri-Gum™ product line in the United Kingdom.  In addition, the Company has retained a full-time salesperson - located in London. The Company expects to substantially increase its sales, in the United Kingdom, throughout the remainder of Calendar Year 2021 and beyond.

Read the original:
Tauriga Sciences Inc. Commences Sales of its Tauri-Gum Product Line in the United Kingdom

To Read More: Tauriga Sciences Inc. Commences Sales of its Tauri-Gum Product Line in the United Kingdom
categoriaGlobal News Feed commentoComments Off on Tauriga Sciences Inc. Commences Sales of its Tauri-Gum Product Line in the United Kingdom | dataJuly 22nd, 2021
Read All

LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare…

By Dr. Matthew Watson

LEXEO obtains exclusive rights to three investigational AAV-mediated gene therapy programs for rare cardiac disorders, all of which have no existing disease-modifying treatments available

See more here:
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare...

To Read More: LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare…
categoriaGlobal News Feed commentoComments Off on LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare… | dataJuly 22nd, 2021
Read All

Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory…

By Dr. Matthew Watson

NEWPORT, United Kingdom and AMSTERDAM, July 21, 2021 (GLOBE NEWSWIRE) -- Nanopharm Ltd., an Aptar Pharma company and leader in contract research and development of orally inhaled and nasally delivered drug products (OINDP) and Leyden Labs, a company targeting commonalities of viral families to protect humanity from known and future viruses, today announced that they have entered into an agreement to develop nasal sprays that may provide broad protection against respiratory viruses, combining Leyden Labs’ portfolio and Nanopharm’s expertise in the development of nasally delivered drug products.

More:
Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory...

To Read More: Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory…
categoriaGlobal News Feed commentoComments Off on Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory… | dataJuly 22nd, 2021
Read All

Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing

By Dr. Matthew Watson

EMERYVILLE, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI) today announced a strategic collaboration with Thermo Fisher Scientific aimed at addressing challenges in commercial-scale viral vector manufacturing. The partnership, which began in December of 2020, brings together Berkeley Lights’ leadership in functional biology characterization with Thermo Fisher’s expertise in viral vector manufacturing and analytics. Together, the companies are collaborating on a next-generation workflow using the Berkeley Lights Platform to accelerate and improve the development of stable AAV (Adeno-Associated Viral) and LV (Lentiviral) vector producer cell lines.

More:
Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing

To Read More: Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing
categoriaGlobal News Feed commentoComments Off on Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing | dataJuly 22nd, 2021
Read All

Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

By Dr. Matthew Watson

- Csiki has over two decades of experience in research and drug development of cancer immunotherapies - - Csiki has over two decades of experience in research and drug development of cancer immunotherapies -

Visit link:
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

To Read More: Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board
categoriaGlobal News Feed commentoComments Off on Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board | dataJuly 22nd, 2021
Read All

Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2…

By Dr. Matthew Watson

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that COVID-19 patients have been dosed in its Phase 2 efficacy trial. Approximately 350 outpatients with COVID-19 who are asymptomatic or have mild symptoms will be enrolled in this large double-blind, randomized clinical trial evaluating COVIDROPS doses of 10 mg or 20 mg against placebo (details can be found on www.ClinicalTrials.gov using the identifier NCT04900428). This study uses a novel decentralized design where subjects are assessed and treated in their homes and received a rapid review and clearance from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.

The rest is here:
Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2...

To Read More: Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2…
categoriaGlobal News Feed commentoComments Off on Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2… | dataJuly 22nd, 2021
Read All

Spectral Medical Inc. Announces $10 Million Offering

By Dr. Matthew Watson

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

The rest is here:
Spectral Medical Inc. Announces $10 Million Offering

To Read More: Spectral Medical Inc. Announces $10 Million Offering
categoriaGlobal News Feed commentoComments Off on Spectral Medical Inc. Announces $10 Million Offering | dataJuly 22nd, 2021
Read All

Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021

By Dr. Matthew Watson

BURBANK, CA, July 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it will hold a webcast and Q&A with the investment community on Tuesday, July 27, at 5 p.m. Eastern Daylight Time.  The purpose of this is to answer questions received from the investment community all at one time in an open forum.

See the original post here:
Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021

To Read More: Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021
categoriaGlobal News Feed commentoComments Off on Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021 | dataJuly 22nd, 2021
Read All

Major Shareholder Announcement

By Dr. Matthew Watson

Company Announcement

View post:
Major Shareholder Announcement

To Read More: Major Shareholder Announcement
categoriaGlobal News Feed commentoComments Off on Major Shareholder Announcement | dataJuly 22nd, 2021
Read All

Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug…

By Dr. Matthew Watson

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today its partner Escugen Biotechnology Co, Ltd. (“Escugen”) and Sorrento’s subsidiary Levena (Suzhou) Biopharma Co., Ltd. (“Levena”) have received an approval letter from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its Application for Clinical Trial (Acceptance No. CXSL2101069) of Recombinant Humanized Anti-Trop2 Mab-SN38 Conjugate.

Follow this link:
Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug...

To Read More: Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug…
categoriaGlobal News Feed commentoComments Off on Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug… | dataJuly 22nd, 2021
Read All

Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update

By Dr. Matthew Watson

STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

Original post:
Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update

To Read More: Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update
categoriaGlobal News Feed commentoComments Off on Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update | dataJuly 22nd, 2021
Read All

ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients

By Dr. Matthew Watson

ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients

Original post:
ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients

To Read More: ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients
categoriaGlobal News Feed commentoComments Off on ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients | dataJuly 22nd, 2021
Read All

Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units

By Dr. Matthew Watson

WINNIPEG, Manitoba, July 21, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has cancelled 8,470,555 stock options of the Company (the “Cancelled Options”) of various directors, officers, employees and consultants of the Company. The Company also wishes to announce the issuance of 10,739,488 restricted share units of the Company (“RSUs”) to various directors, officers, employees and consultants of the Company pursuant to the performance and restricted share unit plan of the Company dated April 21, 2021. Each exchanged RSU is exercisable into one common share of the Company (“Shares”) for a period of ten years from the date of grant. The expiry date of the RSUs and the vesting period of the RSUs vary depending on the participant.

Go here to see the original:
Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units

To Read More: Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units
categoriaGlobal News Feed commentoComments Off on Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units | dataJuly 22nd, 2021
Read All

Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities

By Dr. Matthew Watson

SALT LAKE CITY, July 21, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for a new recommendation statement by the American College of Medical Genetics and Genomics (ACMG), advising that genetic carrier screening be offered to all people who are pregnant or considering a pregnancy. The statement recommends screening for more than 110 genetic disorders regardless of family history or ethnicity. ACMG previously recommended more limited carrier screening and for only certain ethnicities.

Go here to read the rest:
Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities

To Read More: Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities
categoriaGlobal News Feed commentoComments Off on Myriad Genetics Supports New ACMG Recommendation Statement on Increasing Access to Carrier Screening for All Ethnicities | dataJuly 22nd, 2021
Read All

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results

By Dr. Matthew Watson

Basel, 22 July 2021

See the article here:
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results

To Read More: [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results
categoriaGlobal News Feed commentoComments Off on [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results | dataJuly 22nd, 2021
Read All

argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021

By Dr. Matthew Watson

July 22, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, July 29, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2021 financial results and provide a second quarter business update.

Follow this link:
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021

To Read More: argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
categoriaGlobal News Feed commentoComments Off on argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021 | dataJuly 22nd, 2021
Read All

Page 11234..1020..»